PD-L1 expression in primary lung tumor as a superior predictive biomarker to metastatic lymph nodes for first-line immunochemotherapy in advanced KRAS-mutant non-small cell lung cancer.

ABSTRACT:

Background

The correlation between programmed death-ligand 1 (PD-L1) expression and the efficacy of first-line chemoimmunotherapy in advanced KRAS-mutant non-small cell lung cancer (NSCLC) is inconsistent across studies, possibly due to the spatial heterogeneity of PD-L1 expression. We characterized the PD-L1 expression profile at different tumor sites and its impact on the clinical efficacy of first-line immunochemotherapy in advanced KRAS-mutant NSCLC patients.

Methods

A retrospective analysis was performed on 302 patients with advanced KRAS-mutant NSCLC who received first-line immunochemotherapy from January 2018 to December 2022. Patients were categorized by biopsy sites: primary lung lesions (n=211) and metastatic lymph nodes (n=91). PD-L1 expression was stratified into

SUBMITTER: Jin H 

PROVIDER: S-EPMC12683442 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature